Abbott Laboratories v. TorPharm, Inc.’s Empirical Analysis
2004
Citation profile
3 federal appellate ·
Relationships
Applies 28 U.S.C. § 291 · 35 U.S.C. § 271
Relies on Heck v. Humphrey · Zenith Laboratories, Inc. v. Bristol-Myers Squibb Co. · United States v. Husband · Abbott Laboratories v. Torpharm, Inc. · Sandoval v. Acevedo
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 4 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“TorPharm, Inc., Apotex, Inc., Apotex Corp., and their respective affiliates, successors in interest, and assigns are enjoined from commercially manufacturing, using, selling, or offering to sell generic divalproex sodium which the Court has found to be infringing within the United States, or from importing such product into the United States, until Abbott’s U.S. Patent Nos. 4,988,731 and 5,212,326 expire and defendants have received final approval from FDA to market generic divalproex sodium. The effective date of any approval by FDA of ANDA No. 75-112, or any other application concerning defendants’ generic divalproex sodium which the Court has found to be infringing, shall be no earlier than January 29, 2008, the date of expiration of Abbott’s U.S. Patent Nos. 4,988,731 and 5,212,326.”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.